AbbVie completes $63 billion acquisition of El Jian, AstraZeneca reclaims new inflammatory bowel disease drug IL-23 single anti-brazikumab global rights!

May 12, 2020 /
Biovalley BIOON/ -- AstraZeneca recently announced that it has completed the recovery of Brazikumab (formerly MEDI20) from Allergan 70) Global Rights, a monoclonal antibody for leukocyte interleukin 23 (IL-23), treating Crohn's disease (CD) in phase IIb/III clinical, and treatment of ulcerative colitis (UC) in phase IIb clinical AstraZeneca and Aljian have terminated their previous licensing agreements As a result, all rights to brazikumab are now owned by AstraZeneca, which will enhance AstraZeneca's respiratory and immunology pipeline, which is one of the company's three key therapeutic areas, with the other two being Oncology , Cardiovascular and Kidney and Metabolic Diseases On May 8 th this year, AbbVie announced the completion of its acquisition of AlJian The $63 billion acquisition will give birth to a giant biotech company AbbVie is currently ranked 10th on top of top-15, a major pharmaceutical company Pharma, a pharmaceutical market research firm, predicts that AbbVie will jump to fourth place after the acquisition is completed, with sales expected to reach $53.56 billion in 2026 In the agreement between El Jian and AstraZeneca, Under the termination agreement, El-Jian will fund the agreed amount, which is estimated to be the total cost that AstraZeneca is expected to generate prior to the completion of the development of brazikumab for Crohn's disease (CD) and ulcerative colitis (UC), including the development of an accompanying diagnostic product based on the joint development and commercialization of a clinical phase inflammation portfolio (including brazikumab) developed and commercialized by Aachen and AstraZenj in 2012, Amgen is entitled to high-digit to low-digit royalties based on sales, including royalties for the original inventor, if Brazikumab is approved for regulatory approval and listing In addition, AstraZeneca will have full rights and benefits from the drug and will not have to pay any thing else to Amon or Eljian brazikumab is a monoclonal antibody drug capable of binding to IL-23 receptors and is currently being developed to treat Crohn's disease (CD) and ulcerative colitis (UC) with a biomarker brazikumab selectively blocks IL23 immune signals to prevent inflammation of the intestines In Phase II clinical trials, brazikumab showed clinical efficacy in the eighth week of treatment in CD patients with anti-tumor necrosis factor (TNF) Currently, the IIb/III INTREPID project is under way to evaluate the efficacy of the brazikumab, placebo, and adamadaliab treatment CD Another Phase II trial is under way to assess the efficacy of brazikumexpedition, placebo, and Entyvio (vedolizumab) treatment uc for biologics currently on the market, about 40-55% of patients did not respond to these drugs and 65-80% did not receive full remission for treatment currently, AstraZeneca's mid- to late-stage biologics in respiratory and immunology include: (1) Faenra (benralizumab ), a single antidote that has been approved as an additional maintenance therapy for severe eosinophilic glycemic asthma, which is being evaluated for eight eophilic misocya-driven diseases other than severe asthma Faenra is able to directly bind to the alpha sub-sub-base (IL-5R alpha) of the leukocyte interleukin 5 receptor on eosinophils and uniquely attracts naturally killing cells (NK cells) to induce rapid and almost complete depletion of eosinophils by apoptosis (procedural cell death) (2) tezepelumab , this is the first anti-TSLP monoantigen, in phase III clinical treatment of severe, uncontrolled asthma (3) anifrolumab , an all-human monoclonal antibody that binds to type I interferon receptor sub-element 1, treats systemic lupus (SLE) is expected to submit a regulatory application in the second half of 2020, which blocks the activity of all type I interferons, including IFN alpha, IFN beta, and IFN-o, which is a cytokine involved in the inflammatory pathway (4) MEDI3506 , a monoclonal antibody that targets binding leukocyte interleukin 33 (IL33) and is in Phase II clinical treatment for skin diseases and other inflammatory diseases Among the controlled drugs selected by the Brazikumab clinical program, Adamu monotonous (Shumel, Humira) is AbbVie's flagship inflammatory product, the world's first approved anti-
tumor necrosis factor (TNF-alpha) drug, and the world's best-selling anti-inflammatory drug, listed more than 10 years ago, with a number of approved indications, significant efficacy, good safety has been widely recognized has been named the world's "drug king" for eight years in a row since it first won the title of "drug king" in 2012 with sales of $9.596 billion Sales were $19.9 billion in 2018 and $19.169 billion in 2019 By 2019, total global sales of Adamu single-resistant have exceeded $155.1 billion Entyvio is an intestinal selective biologic of Takeda Pharmaceuticals, a monoclonal antibody that specifically antagonist anti-alpha 4beta7 integrators that inhibit the combination of alpha 4 beta7 integrators against the intestinal mucosal cell adhesion molecule MAdCAM-1 MAdCAM-1 is selectively expressed in gastrointestinal blood vessels and lymph nodes Alpha4 beta7 integrators are expressed in a group of circulating white blood cells that have been shown to play an important role in the process of acmediation inflammation of CD and UC diseases , Entyvio intravenous preparations (IV) are currently on the market in more than 60 countries around the world, and subcutaneous preparations (SCs) have recently been approved by the European Union It is worth noting that Entyvio is the only european approved maintenance therapy for both intravenous preparations (IV) and subcutaneous preparations (SCs) for both UC and CD adult patients, providing patients with more choices in treatment In China, Entyvio IV (Angelo ®, Vedolizumab, injection Vedrezumab) was approved in March this year for moderate to severe active UC and CD patients who had inadequate, unresponsive or intolerant responses to traditional treatments or TNF alpha inhibitors Entyvio (Angelo ®) was included in the first batch of clinically urgently needed of new drugs abroad and received an accelerated review Entyvio (Angie ®) is the only intestinal selective biologic in the field of inflammatory bowel disease (IBD), whose clinical data show that it can quickly start effectively and achieve long-lasting clinical remission and mucous membrane healing, while being safe, is the first-line biologic recommended by international guidelines in Europe and the United States 's inclusion in the first batch of clinically urgent overseas new drugs from the Angie ® (Injecting Vidli-Ziti) to its rapid approval is a testament to the Chinese government's determination to accelerate the introduction of innovative drugs and continuously improve people's healthy lives The approved launch of the drug in China will provide a new treatment option for a large number of patients with moderate to severe IBD in China (biovalleybioon.com) original source: Atra Zeneca Recovery of global right to brazikumab (MEDI2070) from Allergan completed